Protein kinase inhibitors

C-Raf Kinase Inhibitor Pipeline Insight Report 2020: HyNap-Sora, Sorafenib/MG 010, APL-102, & BAL 3833 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 5, 2021
Health, Pharmaceutical, Enzymes, Protein kinases, c-Raf, Protein kinase inhibitors, Oncogenes, Tyrosine kinase inhibitors

The "C-Raf Kinase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "C-Raf Kinase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "C-Raf Kinase Inhibitor- Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-Raf Kinase Inhibitor pipeline landscape.
  • This segment of the report provides insights about the different C-Raf Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • C-Raf Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027

Retrieved on: 
Friday, February 5, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Intellectual property law, Organic compounds, Intangible assets, Protein kinase inhibitors, Cyclopentanes, Piperazines, Breakthrough therapy, Palbociclib, United States Patent and Trademark Office, Term of patent in the United States, Term of patent, IBRANCE® (palbociclib) 125 mg tablets and capsules, Pfizer Oncology, Pfizer: Breakthroughs That Change Patients’ Lives

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE (palbociclib).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE (palbociclib).
  • The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984.
  • In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole.
  • In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant.

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-192 in the U.S.

Retrieved on: 
Thursday, February 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cholangiocarcinoma, Hepatology, Cancer, Medical specialties, Breakthrough therapy, Protein kinase inhibitors, Orphan drugs

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.

Key Points: 
  • InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.
  • ICP-192 is a highly selective small-molecule pan-FGFR inhibitor for the treatment of various solid tumors with FGFR aberrations.
  • Currently it is in Phase I/II clinical studies in China and the United States.
  • The Phase II trial in China is a multi-center, open-label clinical trial designed to evaluate the safety and efficacy of ICP-192 in patients with advanced cholangiocarcinoma and urothelial cancer that have FGFR aberrations.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Retrieved on: 
Wednesday, February 3, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Enzymes, Tyrosine-protein kinase SYK, Tyrosine kinase, Jak, Drugs, Tyrosine kinase inhibitors, Orphan drugs, Protein kinase inhibitors, Indazoles, Cerdulatinib, Janus kinase inhibitor

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients

Retrieved on: 
Thursday, December 17, 2020
Breast cancer, Cancer, Health, Aminopyridines, Protein kinase inhibitors, Kathleen I. Pritchard, Breast cancer management

San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9that this years San Antonio Breast Cancer Symposium.

Key Points: 
  • San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9that this years San Antonio Breast Cancer Symposium.
  • The Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial examined the Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio and its ability to predict benefit from extended endocrine therapy.
  • The Breast Cancer Index (BCI) allows us to sort out the patients who will benefit from extended endocrine therapy from those who will not (but who will suffer the harms).
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer.

BerGenBio (BGBIO): Progressing towards key inflection points

Retrieved on: 
Thursday, December 17, 2020
Protein kinase inhibitors, Acute myeloid leukemia, Myelodysplastic syndrome, Bemcentinib, Clinical medicine, Orphan drugs, Chemical substances, Health, Alkaloids

BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020.

Key Points: 
  • BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020.
  • We still forecast the NDA submission for this indication in 2023 (FDA fast-track has been granted).
  • We continue to value BerGenBio at NOK5.16bn or NOK59.1 per share based on a risk-adjusted NPV analysis.
  • The key drivers are bemcentinib in second-line NSCLC (peak sales $1.2bn, NOK40.7/share) and AML (peak sales $588m, NOK13.3/share) plus COVID-19 opportunity (NOK5.9/share).

AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020

Retrieved on: 
Thursday, December 17, 2020
Medicine, Clinical medicine, Cancer, Protein kinase inhibitors, Masitinib, Tyrosine kinases, Cancer treatments, Tyrosine kinase, Kinase, Oncology, ABL, Immunotherapy

AB Science SA (Euronext - FR0010557264 - AB) today announced that the press release issued on December 16, 2020 regarding the results from study AB09004, which evaluated masitinib in the treatment of Alzheimer disease, contained a material error in the adverse events information reported.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that the press release issued on December 16, 2020 regarding the results from study AB09004, which evaluated masitinib in the treatment of Alzheimer disease, contained a material error in the adverse events information reported.
  • Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
  • In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Retrieved on: 
Tuesday, December 15, 2020
Clinical medicine, Drugs, Cancer treatments, Devimistat, Thioethers, Orphan drugs, Protein kinase inhibitors, Myelodysplastic syndrome, Leukemia, Acute myeloid leukemia, Vadastuximab talirine, Bemcentinib

While one of the most common types of leukemia in adults, AML accounts for only 1% of all cancers .

Key Points: 
  • While one of the most common types of leukemia in adults, AML accounts for only 1% of all cancers .
  • This announcement comes on the heels of the Company receiving Fast Track designation for devimistat for the treatment of metastatic pancreatic cancer , in November.
  • The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukemia.
  • Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Burkitts,peripheral T-cell lymphomas and soft tissue sarcoma.

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

Retrieved on: 
Monday, December 14, 2020
Chemical compounds, Branches of biology, Organic compounds, Cell Cycle, Protein kinase inhibitors, Cyclopentanes, Breakthrough therapy, Palbociclib, Piperazines, Cyclin-dependent kinase, Androgen receptor, Metastatic breast cancer

In metastatic breast cancer, prior treatment with CDK4/6 inhibitors predicts high tumor ER-independence, rendering ER-targeting therapies ineffective.

Key Points: 
  • In metastatic breast cancer, prior treatment with CDK4/6 inhibitors predicts high tumor ER-independence, rendering ER-targeting therapies ineffective.
  • Arvinas also expects to initiate a Phase 1b cohort expansion of ARV-471 in combination with Ibrance (palbociclib) in December 2020.
  • Arvinas will host a conference call and webcast at 8:00 AM ET on Monday, December 14, 2020 to discuss these data.
  • ARV-110 is an investigational orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor (AR).

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of TrodelvyTM (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020
Chemical compounds, Clinical medicine, Organic compounds, Breast cancer, Protein kinase inhibitors, HER2/neu, Metastatic breast cancer, Cancer, CDK inhibitor, Triple-negative breast cancer

The primary endpoint is progression free survival (PFS) per RECIST v1.1 by an Independent Review Committee.

Key Points: 
  • The primary endpoint is progression free survival (PFS) per RECIST v1.1 by an Independent Review Committee.
  • HR+/HER2- breast cancer is the most prevalent subtype of breast cancer and accounts for more than 60% of all breast cancer cases.
  • Hormone Receptor Positive, HER2 Negative (HR+/HER2-) breast cancer is the most common form of breast cancer in China, representing over 60% of all breast cancer cases.
  • This subtype of breast cancer grows in connection with estrogen or progesteroneand is likely to respond to hormone therapies initially, but almost all HR+/HER2- metastatic breast cancers becomerefractory over time.